Novartis sees India Glivec ruling indicative of IP 'de-recognition'
This article was originally published in Scrip
Executive Summary
India's Supreme Court has dismissed with costs Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law (scripintelligence.com, 1 April 2013).
You may also be interested in...
Patent Win For Sofosbuvir In India But "Tortured" Ruling Faces Appeal
India has approved a Gilead Sciences Inc. patent that claims the active metabolites of sofosbuvir amid allegations by opponents of "external pressures" on the patent office and that the decision "weakens" Section 3(d) of India's patent regulation.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.